Esperion reports Q2 EPS (33c), consensus (17c)

Reports Q2 revenue $73.8M, consensus $49.06M. Cash and Cash Equivalents. As of June 30 cash and cash equivalents totaled $189.3M compared to $82.2M as of December 31, 2023. “Throughout the Q2, we continued to execute our strategy across all key areas of our business that are important for long-term success and value creation,” stated Sheldon Koenig, President and CEO of Esperion. “In addition to achieving notable growth in U.S. product revenue, we made great inroads updating utilization management criteria across multiple payers, which underscores their recognition of the potential clinical benefits for patients who are unable to achieve their LDL-C goals or reduce their cardiovascular risk with current therapies and paves the way for further prescription growth and increasing product revenue. In collaboration with our global partners, we made great strides expanding our international reach, which we believe will be a meaningful revenue driver over time.”